ADAR1 Partners just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on ADAR1 Partners, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Adar1 Partners Increases Stake in Keros Therapeutics with $9.1M Purchase
Contract Type
partnership
Description
Adar1 Partners, LP, a significant stakeholder in Keros Therapeutics, Inc. (NASDAQ:), has increased its stake in Keros Therapeutics with a $9.1 million purchase, acquiring a total of 939,698 shares of Keros Therapeutics’ common stock. The investment reflects ADAR1’s continued confidence in Keros, a pharmaceutical company engaged in the development of novel treatments for hematologic and musculoskeletal disorders.